FTN Equity Starts Mylan Labs (MYL) at Neutral
More News related to MYL
- Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
- Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by Elsevier
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
- Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
More News related to New Coverage
- Financial Group Moving Higher Amid BofA TARP Repayment News (BAC, C, WFC, XLF, FAS)
- Lexington Realty Trust (LXP) Sells Office Facility in Columbia, SC
- BofA (BAC) Confirms That It Will Repay $45B in TARP Funds
- EQT Corp.'s (EQT) Board Approves Capital Budget for 2010
- Morgan Stanley (MS) may restructure its real estate fund -WSJ
FTN Equity initiates coverage on Mylan Labs (NYSE: MYL) with a Neutral rating.
For more analyst ratings on MYL click here.
Mylan Inc. and its subsidiaries engage in the development, manufacture, marketing, licensing, and distribution of generic, brand, and branded generic pharmaceutical products and active pharmaceutical ingredients (APIs).
Related Categories
New CoverageStocks Mentioned
+0.28Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
